Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Rocket Pharmaceuticals initiated with an Overweight at JPMorgan » 08:26
07/02/20
07/02
08:26
07/02/20
08:26
RCKT

Rocket Pharmaceuticals

$20.50 /

-0.42 (-2.01%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph initiated coverage of Rocket Pharmaceuticals with an Overweight rating and $38 price target. The company is advancing a "differentiated" gene therapy platform that is well positioned against multiple rare pediatric diseases with either "first- or best-in-class product candidates," Joseph tells investors in a research note. Rocket's pipeline "boasts multiple shots on goal, the majority of which offering rapid timelines to commercialization," says the analyst.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$20.50 /

-0.42 (-2.01%)

RCKT Rocket Pharmaceuticals
$20.50 /

-0.42 (-2.01%)

06/25/20 BofA
Rocket Pharmaceuticals reinstated with a Buy at BofA
06/25/20 BofA
Rocket Pharmaceuticals reinstated with a Buy at BofA
05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
RCKT Rocket Pharmaceuticals
$20.50 /

-0.42 (-2.01%)

  • 11
    Dec
Over a week ago
Initiation
Rocket Pharmaceuticals reinstated with a Buy at BofA » 07:32
06/25/20
06/25
07:32
06/25/20
07:32
RCKT

Rocket Pharmaceuticals

$21.30 /

-1.495 (-6.56%)

BofA analyst Greg…

BofA analyst Greg Harrison reinstated coverage of Rocket Pharmaceuticals with a Buy rating and $34 price target. Harrison forecasts revenues for the four main programs in the sub-$1B range, though the collective opportunity reaches $1.6B in 2030 using quite conservative penetration assumptions, leaving meaningful room for upside should gene therapy become more widespread in these indications.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$21.30 /

-1.495 (-6.56%)

RCKT Rocket Pharmaceuticals
$21.30 /

-1.495 (-6.56%)

06/25/20 BofA
Rocket Pharmaceuticals reinstated with a Buy at BofA
05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
RCKT Rocket Pharmaceuticals
$21.30 /

-1.495 (-6.56%)

Initiation
Rocket Pharmaceuticals reinstated with a Buy at BofA » 06:25
06/25/20
06/25
06:25
06/25/20
06:25
RCKT

Rocket Pharmaceuticals

$21.30 /

-1.495 (-6.56%)

BofA analyst Greg…

BofA analyst Greg Harrison reinstated coverage of Rocket Pharmaceuticals with a Buy rating and $34 price target.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$21.30 /

-1.495 (-6.56%)

RCKT Rocket Pharmaceuticals
$21.30 /

-1.495 (-6.56%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
RCKT Rocket Pharmaceuticals
$21.30 /

-1.495 (-6.56%)

Conference/Events
Rocket Pharmaceuticals participates in a conference call with Cowen » 10:25
06/24/20
06/24
10:25
06/24/20
10:25
RCKT

Rocket Pharmaceuticals

$21.78 /

-1.015 (-4.45%)

Healthcare Analyst Werber…

Healthcare Analyst Werber holds a conference call with management on June 24 at 11 am hosted by Cowen.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$21.78 /

-1.015 (-4.45%)

RCKT Rocket Pharmaceuticals
$21.78 /

-1.015 (-4.45%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
RCKT Rocket Pharmaceuticals
$21.78 /

-1.015 (-4.45%)

Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

Frequency Therapeutics

$22.68 /

-0.47 (-2.03%)

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

Conference/Events
Rocket Pharmaceuticals participates in a conference call with Cowen » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

Healthcare Analyst Werber…

Healthcare Analyst Werber holds a conference call with management on June 24 at 11 am hosted by Cowen.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

Conference/Events
Rocket Pharmaceuticals participates in a conference call with Cowen » 10:22
06/22/20
06/22
10:22
06/22/20
10:22
RCKT

Rocket Pharmaceuticals

$21.28 /

-0.29 (-1.34%)

Healthcare Analyst Werber…

Healthcare Analyst Werber holds a conference call with management on June 24 at 11 am hosted by Cowen.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$21.28 /

-0.29 (-1.34%)

RCKT Rocket Pharmaceuticals
$21.28 /

-0.29 (-1.34%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
RCKT Rocket Pharmaceuticals
$21.28 /

-0.29 (-1.34%)

Over a month ago
Recommendations
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler » 10:40
05/13/20
05/13
10:40
05/13/20
10:40
RCKT

Rocket Pharmaceuticals

$19.44 /

+0.17 (+0.88%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren says both of Rocket Pharmaceuticals' lentiviral programs look even more promising post the American Society of Gene and Cell Therapy presentations. Both programs are further de-risked and continue to appear promising based on the existing data, Van Buren tells investors in a research note. He keeps an Overweight rating on Rocket Pharmaceuticals with a $35 price target.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$19.44 /

+0.17 (+0.88%)

RCKT Rocket Pharmaceuticals
$19.44 /

+0.17 (+0.88%)

03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
RCKT Rocket Pharmaceuticals
$19.44 /

+0.17 (+0.88%)

RCKT Rocket Pharmaceuticals
$19.44 /

+0.17 (+0.88%)

Hot Stocks
Rocket Pharmaceuticals presents new clinical data on FA, LAD-I at ASGCT » 07:06
05/12/20
05/12
07:06
05/12/20
07:06
RCKT

Rocket Pharmaceuticals

$19.19 /

+1.55 (+8.79%)

Rocket Pharmaceuticals…

Rocket Pharmaceuticals presents new clinical data supporting longer-term efficacy and durability of gene therapy for Fanconi Anemia, or FA, and Leukocyte Adhesion Deficiency-I, or LAD-I, at the annual meeting of the American Society of Gene and Cell Therapy, or ASGCT. Two oral presentations highlight updates from the company's Phase 1/2 study of RP-L201 for the treatment of severe LAD-I and the Phase 1/2 study of RP-L102 "Process A" for the treatment of FA. Additional results from the first patient treated with RP-L201 for LAD-I continue to demonstrate evidence of safety and potential efficacy. Analyses of peripheral vector copy number, or VCN, and CD18-expressing neutrophils were performed six months post treatment with RP-L201 to evaluate engraftment and phenotypic correction. The patient demonstrated peripheral blood VCN levels of 1.3 and CD18-expression of 47%, which is sustained from the 45% expression observed three months post treatment; pretreatment CD18 expression was less than 1%. The drug product VCN was 3.8. Additionally, the patient continues to display visible improvement of skin lesions. No safety or tolerability issues related to RP-L201 administration have been identified to date. RP-L201 was in-licensed from the Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas, Centro de Investigacion Biomedica en Red de Enfermedades Raras and Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz. The lentiviral vector was developed in a collaboration between The University College of London and CIEMAT. Nine pediatric patients have been enrolled and treated in the Phase 1/2 clinical trial of RP-L102 "Process A" for the treatment of Fanconi Anemia, seven of whom are evaluable at or beyond the one year mark following treatment. The first four patients exhibit robust and durable engraftment, continued hematologic correction and blood count stabilization. Importantly, hemoglobin levels for patients 02002 and 02006 have increased to a healthy, normal range; these patients received more optimal product consistent with the minimal dose criteria established for the "Process B" registrational program. Two additional patients who have been followed for a year or more after treatment display early evidence of engraftment, as measured by increases in peripheral blood VCNs. Patient 02007 received a lower than optimal dose and is beginning to demonstrate preliminary signs of engraftment. Blood counts are not yet available in these patients. Two patients, patients 01003 and 02009, have not been included in this analysis. Patient 02009 is only six months post treatment and will continue to be followed. Patient 01003 received a drug product that did not meet full release criteria due to a technical issue - this was a one-time lab-specific issue that was addressed. To date, no patients in this trial have undergone allogeneic bone marrow transplant.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$19.19 /

+1.55 (+8.79%)

RCKT Rocket Pharmaceuticals
$19.19 /

+1.55 (+8.79%)

03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
RCKT Rocket Pharmaceuticals
$19.19 /

+1.55 (+8.79%)

RCKT Rocket Pharmaceuticals
$19.19 /

+1.55 (+8.79%)

Earnings
Rocket Pharmaceuticals reports Q1 EPS (45c), consensus (49c) » 07:37
05/06/20
05/06
07:37
05/06/20
07:37
RCKT

Rocket Pharmaceuticals

$17.00 /

+1.47 (+9.47%)

"During the first…

"During the first quarter, we continued to advance five programs across both the AAV and Lenti platforms," said Gaurav Shah, M.D., CEO and President of Rocket. "Notably this quarter, we completed patient treatment in the low dose cohort for RP-A501 in the Phase 1 Danon Disease trial with no dose-limiting toxicities, and are now pleased to report FDA and IDSMC clearance to advance to a higher dose cohort. This has been an important priority for us as Danon Disease affects so many young patients with devastating heart, muscle and CNS manifestations. We also continued to progress our clinical programs for FA, LAD-I, and PKD. Rocket is at an exciting stage of growth, with a rich pipeline of development-stage opportunities and the potential to transform the lives of patients afflicted with rare disease. In the coming months, we look forward to presenting updated FA 'Process A' and LAD-I 'Process B' data at ASGCT, treating our first patient in a higher dose cohort for RP-A501, and bringing our fifth program, IMO, to the clinic." Dr. Shah continued, "With regard to the COVID-19 pandemic, we are well-positioned overall to continue our progress while we monitor and adjust to this challenging global crisis. We have experienced modest COVID-19-related pauses in patient enrollment and follow-up that are being managed on a patient-by-patient basis, along with some delays in data collection. Nonetheless, we remain on track for providing updates on our lentiviral pipeline. Assuming that COVID-19 associated delays have shorter-term impact, we remain committed to providing data for Danon by the end of the year. Lastly, we continue to actively monitor the pandemic and refine operations to support the complete safety and well-being of our patients, employees and community."

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$17.00 /

+1.47 (+9.47%)

03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.